[Effects of guaiacolic ester of acetylsalicylic acid on spirometric and plethysmographic parameters in subjects with chronic obstructive bronchopneumopathy].
The effects of oral administration of guaiacolic ester of acetyl salicilic acid in 24 patients with chronic obstructive lung disease have been evaluated. 1.5 g of this drug were given daily into 3 administrations improving both objective and subjective symptomatology in 19 of the 24 patients after 1 or 3 weeks of treatment. Moreover, a statistically significant improvement of FEV 1" (p less than 0.001), Raw (p less than 0.005) and FEV 1"/VC (p less than 0.01) was observed. The remaining 5 patients discontinued the treatment failing the improvement of the subjective symptomatology.
D000368:Aged; D001241:Aspirin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012119:Respiration / Q000187:drug effects; D012129:Respiratory Function Tests
D001241:Aspirin; C023557:guacetisal
Effetti dell'estere guaiacolico dell'acido acetilsalicilico su alcuni parametri spirometrici e pletismografici in soggetti affetti da broncopneumopatia cronica ostruttiva.